Study on the protective efect and mechanism of paeoniflorin on palmitic acid-induced HepG2 cells

Tong LIU; Shanzheng LI; Cheng ZHOU; Sutong LIU; Lihui ZHANG; Wenxia ZHAO

doi:10.12449/JCH250316

Volume 41 Issue 3

Mar. 2025

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2025 > 41(3): 499-505

PDF( 2930 KB)

Study on the protective efect and mechanism of paeoniflorin on palmitic acid-induced HepG2 cells

DOI: 10.12449/JCH250316

Tong LIU^{1, 2},
Shanzheng LI^{1, 2},
Cheng ZHOU^{1, 2},
Sutong LIU¹,
Lihui ZHANG¹,
Wenxia ZHAO^{1
,
,
,}

1.
Department of Hepatobiliary，Spleen and Stomach Diseases，The First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450003，China
2.
The First Clinical Medical College of Henan University of Chinese Medicine，Zhengzhou 450046，China

Research funding:

National Natural Science Foundation of China (82205086);

Key Project of Traditional Chinese Medicine Science Research in Henan Province (2022JDZX006);

Project of Henan Provincial Health Commission (2022JDZX114);

Henan Province Science and Technology Attack Fund (232102310438)

More Information

Corresponding author: ZHAO Wenxia， zhao-wenxia@163.com （ORCID： 0000-0001-6666-9469）
Received Date: 2024-07-08
Accepted Date: 2024-07-29
Published Date: 2025-03-25

Abstract

Abstract

Objective To investigate the role and mechanism of action of paeoniflorin （PF） in protecting HepG2 cells induced by palmitic acid （PA）. Methods HepG2 cells were stimulated with PA at a concentration of 250 μmol/L to establish a NAFLD model. Compound C at a concentration of 10 μmol/L was used as an inhibitor， and PF at a concentration of 25 μmol/L was used for intervention. The experiment was divided into normal group （CON group） treated with complete culture medium， model group （MOD group） treated with PA， PF treatment group （MOD+PF group） treated with PA and PF， model+inhibitor group （MOD+COM group） treated with PA and Compound C， and model+inhibitor+PF group （MOD+COM+PF group） treated with PA， Compound C， and PF. Kits were used to measure lipid deposition indicators， liver function parameters， oxidative stress indicators， and inflammation indicators； oil red O staining was used to observe lipid deposition； Western Blot was used to measure the protein expression levels of AMPK， SIRT1， PGC-1α， mTOR， Beclin-1， LC3， and P62 in cells. The one-way analysis of variance was used for comparison of quantitative data between groups， while the Tukey’s test was used for comparison between two groups. Results Compared with the MOD group， PF improved the levels of TC and TG （P<0.05）， reduced the levels of ALT， AST， CRP， TNF-α， IL-1β， and IL-6 （P<0.05）， increased the activity of SOD and CAT and the level of GSH， and reduced the level of MDA in cells （all P<0.05）. Oil red O staining showed that PF alleviated lipid deposition in cells. Western blot results showed that compared with the MOD group， PF increased the protein expression levels of p-AMPK， SIRT1， PGC-1α， LC3Ⅱ/LC3Ⅰ， and Beclin-1 and reduced the protein expression levels of p-mTOR and P62 （all P<0.05）. Conclusion PF can inhibit PA-induced oxidative stress and inflammatory response in HepG2 cells， improve lipid deposition， and promote autophagy via the AMPK/SIRT1/PGC-1α/mTOR signaling pathway.
- Non-alcoholic Fatty Liver Disease,
- Paeoniflorin,
- Hep G2 Cells

FullText(HTML)

References(25)

References

[1]	MARGINI C, DUFOUR JF. The story of HCC in NAFLD: From epidemiology, across pathogenesis, to prevention and treatment[J]. Liver Int, 2016, 36( 3): 317- 324. DOI: 10.1111/liv.13031.
[2]	SCHUSTER S, CABRERA D, ARRESE M, et al. Triggering and resolution of inflammation in NASH[J]. Nat Rev Gastroenterol Hepatol, 2018, 15( 6): 349- 364. DOI: 10.1038/s41575-018-0009-6.
[3]	WEI SL, WANG L, EVANS PC, et al. NAFLD and NASH: Etiology, targets and emerging therapies[J]. Drug Discov Today, 2024, 29( 3): 103910. DOI: 10.1016/j.drudis.2024.103910.
[4]	DAY EA, FORD RJ, STEINBERG GR. AMPK as a therapeutic target for treating metabolic diseases[J]. Trends Endocrinol Metab, 2017, 28( 8): 545- 560. DOI: 10.1016/j.tem.2017.05.004.
[5]	WEI ZH, XIA JY, LI JT, et al. SIRT1 promotes glucolipid metabolic conversion to facilitate tumor development in colorectal carcinoma[J]. Int J Biol Sci, 2023, 19( 6): 1925- 1940. DOI: 10.7150/ijbs.76704.
[6]	LIAO JB, XIE XH, WANG N, et al. Formononetin promotes fatty acid β‍-oxidation to treat non-alcoholic steatohepatitis through SIRT1/PGC-1α/PPARα pathway[J]. Phytomedicine, 2024, 124: 155285. DOI: 10.1016/j.phymed.2023.155285.
[7]	KIM YC, GUAN KL. mTOR: A pharmacologic target for autophagy regulation[J]. J Clin Invest, 2015, 125( 1): 25- 32. DOI: 10.1172/JCI73939.
[8]	ZHANG J, FENG QS. Pharmacological effects and molecular protective mechanisms of Astragalus polysaccharides on nonalcoholic fatty liver disease[J]. Front Pharmacol, 2022, 13: 854674. DOI: 10.3389/fphar.2022.854674.
[9]	ZHOU YX, GONG XH, ZHANG H, et al. A review on the pharmacokinetics of paeoniflorin and its anti-inflammatory and immunomodulatory effects[J]. Biomed Pharmacother, 2020, 130: 110505. DOI: 10.1016/j.biopha.2020.110505.
[10]	NAGAPPAN A, KIM JH, JUNG DY, et al. Cryptotanshinone from the Salvia miltiorrhiza bunge attenuates ethanol-induced liver injury by activation of AMPK/SIRT1 and Nrf2 signaling pathways[J]. Int J Mol Sci, 2019, 21( 1): 265. DOI: 10.3390/ijms21010265.
[11]	LAN T, YU Y, ZHANG J, et al. Cordycepin ameliorates non-alcoholic steatohepatitis by activation of the AMP-activated protein kinase signaling pathway[J]. Hepatology, 2021, 74( 2): 686- 703. DOI: 10.1002/hep.31749.
[12]	PATERNOSTRO R, TRAUNER M. Current treatment of non-alcoholic fatty liver disease[J]. J Intern Med, 2022, 292( 2): 190- 204. DOI: 10.1111/joim.13531.
[13]	GUO XY, YIN XZ, LIU ZJ, et al. Non-alcoholic fatty liver disease(NAFLD) pathogenesis and natural products for prevention and treatment[J]. Int J Mol Sci, 2022, 23( 24): 15489. DOI: 10.3390/ijms232415489.
[14]	XIAO Q, ZHANG SJ, YANG C, et al. Ginsenoside Rg1 ameliorates palmitic acid-induced hepatic steatosis and inflammation in HepG2 cells via the AMPK/NF-κB pathway[J]. Int J Endocrinol, 2019, 2019: 7514802. DOI: 10.1155/2019/7514802.
[15]	CHEN MX, HUANG NQ, LIU J, et al. AMPK: A bridge between diabetes mellitus and Alzheimer’s disease[J]. Behav Brain Res, 2021, 400: 113043. DOI: 10.1016/j.bbr.2020.113043.
[16]	STEINBERG GR, HARDIE DG. New insights into activation and function of the AMPK[J]. Nat Rev Mol Cell Biol, 2023, 24( 4): 255- 272. DOI: 10.1038/s41580-022-00547-x.
[17]	YANG YS, LIU Y, WANG YW, et al. Regulation of SIRT1 and its roles in inflammation[J]. Front Immunol, 2022, 13: 831168. DOI: 10.3389/fimmu.2022.831168.
[18]	QIAN L, ZHU YL, DENG C, et al. Peroxisome proliferator-activated receptor gamma coactivator-1(PGC-1) family in physiological and pathophysiological process and diseases[J]. Signal Transduct Target Ther, 2024, 9( 1): 50. DOI: 10.1038/s41392-024-01756-w.
[19]	THIRUPATHI A, de SOUZA CT. Multi-regulatory network of ROS: The interconnection of ROS, PGC-1 alpha, and AMPK-SIRT1 during exercise[J]. J Physiol Biochem, 2017, 73( 4): 487- 494. DOI: 10.1007/s13105-017-0576-y.
[20]	QIAN H, CHAO XJ, WILLIAMS J, et al. Autophagy in liver diseases: A review[J]. Mol Aspects Med, 2021, 82: 100973. DOI: 10.1016/j.mam.2021.100973.
[21]	BYRNES K, BLESSINGER S, BAILEY NT, et al. Therapeutic regulation of autophagy in hepatic metabolism[J]. Acta Pharm Sin B, 2022, 12( 1): 33- 49. DOI: 10.1016/j.apsb.2021.07.021.
[22]	MARCONDES-DE-CASTRO IA, REIS-BARBOSA PH, MARINHO TS, et al. AMPK/mTOR pathway significance in healthy liver and non-alcoholic fatty liver disease and its progression[J]. J Gastroenterol Hepatol, 2023, 38( 11): 1868- 1876. DOI: 10.1111/jgh.16272.
[23]	HWANG HY, SHIM JS, KIM D, et al. Antidepressant drug sertraline modulates AMPK-MTOR signaling-mediated autophagy via targeting mitochondrial VDAC1 protein[J]. Autophagy, 2021, 17( 10): 2783- 2799. DOI: 10.1080/15548627.2020.1841953.
[24]	KMA L, BARUAH TJ. The interplay of ROS and the PI3K/Akt pathway in autophagy regulation[J]. Biotechnol Appl Biochem, 2022, 69( 1): 248- 264. DOI: 10.1002/bab.2104.
[25]	ZHOU B, ZHANG J, CHEN YX, et al. Puerarin protects against sepsis-induced myocardial injury through AMPK-mediated ferroptosis signaling[J]. Aging(Albany NY), 2022, 14( 8): 3617- 3632. DOI: 10.18632/aging.204033.

Relative Articles

[1]	Tianhui LIU. Role of organelle interaction in the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(1): 181-187. doi: 10.3969/j.issn.1001-5256.2023.01.028
[2]	Jingya YIN, Bingqing YANG, Yue LI. Role of pyroptosis in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(1): 175-180. doi: 10.3969/j.issn.1001-5256.2023.01.027
[3]	Yuesheng LIAO, Lili BAI. Role of exercise-induced autophagy in prevention and treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(5): 1156-1160. doi: 10.3969/j.issn.1001-5256.2022.05.038
[4]	Xuelian GU, Junfeng LI, Xiaorong MAO. Research advances in nonalcoholic fatty liver disease-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(1): 196-200. doi: 10.3969/j.issn.1001-5256.2022.01.034
[5]	Juan WANG, Yingchun WANG, Chunyu WANG. Association between monocyte-to-high-density lipoprotein cholesterol ratio and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(5): 1137-1141. doi: 10.3969/j.issn.1001-5256.2021.05.031
[6]	Yalan LEI, Jian BI, Jingwei MAO. Impact of nonalcoholic fatty liver disease on intestinal immune cells[J]. Journal of Clinical Hepatology, 2021, 37(11): 2667-2671. doi: 10.3969/j.issn.1001-5256.2021.11.039
[7]	Shiyan YAN, Jiangao FAN. Diagnosis and treatment of hepatocellular carcinoma associated with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(8): 1748-1752. doi: 10.3969/j.issn.1001-5256.2021.08.002
[8]	YANG Jing, GAO Hong, ZHAO YaoWei, WANG Rui. Role of liver sinusoidal endothelial cells in the pathogenesis of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2601-2605. doi: 10.3969/j.issn.1001-5256.2020.11.046
[9]	Jiang Zhao, Ruan Bo. The role of liver sinusoidal endothelial cells in the progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(3): 684-686. doi: 10.3969/j.issn.1001-5256.2020.03.047
[10]	Zhang YongChao, Li Wei. Association between diabetes and nonalcoholic fatty liver disease-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(10): 2329-2332. doi: 10.3969/j.issn.1001-5256.2020.10.037
[11]	Yan HongMei. Can type 2 diabetes mellitus be reversed by improving nonalcoholic fatty liver disease?[J]. Journal of Clinical Hepatology, 2020, 36(6): 1213-1216. doi: 10.3969/j.issn.1001-5256.2020.06.004
[12]	Xie HaiPing, Lin Fan, Chen Yan, Zheng Ming. Advances in liraglutide in the treatment of type 2 diabetes with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(9): 2111-2114. doi: 10.3969/j.issn.1001-5256.2020.09.046
[13]	Luo Yan, Shi JunPing. Research advances in the pathogenesis of nonalcoholic fatty liver disease-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(6): 1217-1220. doi: 10.3969/j.issn.1001-5256.2020.06.005
[14]	Luo YuXin, Guo JinBo, Zhang XiaoLan. Research advances in the role of macrophages in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(3): 680-683. doi: 10.3969/j.issn.1001-5256.2020.03.046
[15]	Zhou ZhenHua, Wang LingTai, Gao YueQiu. Role of hepatocyte mitophagy in the pathogenesis of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(12): 2809-2811. doi: 10.3969/j.issn.1001-5256.2019.12.036
[16]	Liu SuTong, Zhao WenXia. Research advances in the pathogenesis of nonalcoholic fatty liver disease-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(7): 1621-1625. doi: 10.3969/j.issn.1001-5256.2019.07.043
[17]	Chinese Society of EndocrinologyChinese Medical Association. Consensus for diagnosis and treatment of nonalcoholic fatty liver diseases and metabolic disorders (2nd Edition)[J]. Journal of Clinical Hepatology, 2018, 34(10): 2103-2108. doi: 10.3969/j.issn.1001-5256.2018.10.010
[18]	Gui WenFang, Zhu QingJing, Yang Ling. Research advances in nonalcoholic fatty liver disease-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(12): 2693-2697. doi: 10.3969/j.issn.1001-5256.2018.12.040
[19]	Du SenRong, Mao XiaoRong, Xiao Ping, Chen Hong. Effects of PARP-1 inhibitors AG-014699 and AZD2281 on proliferation and apoptosis of human hepatoma cell line HepG2[J]. Journal of Clinical Hepatology, 2015, 31(6): 943-946. doi: 10.3969/j.issn.1001-5256.2015.06.027
[20]	Zhang JianJun, Wu LiPing, Du RuiQing, Wang JianBin, Yao ZhanCheng, Yu GuiQin. Factors correlating with the liver inflammation grade ≥G2 in chronic HBV-infected patients with normal liver function[J]. Journal of Clinical Hepatology, 2012, 28(1): 35-38.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(8)

Get Citation

PDF

XML

Article Metrics

Article views (48) PDF downloads(6)

Study on the protective efect and mechanism of paeoniflorin on palmitic acid-induced HepG2 cells

DOI: 10.12449/JCH250316

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Study on the protective efect and mechanism of paeoniflorin on palmitic acid-induced HepG2 cells

DOI: 10.12449/JCH250316

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content